Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in TWST.

← Back to Free Index

TWST

Analysis as of: 2026-02-13

Twist Bioscience Corporation

Twist Bioscience manufactures synthetic DNA products (genes, oligos, libraries, and related NGS application consumables) for biopharma, diagnostics, industrial, and academic customers.

ai automation biotech hardware healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

DNA-writing scale meets a profitability gate

AI-driven iteration can expand demand for synthetic DNA, but value capture hinges on durable unit economics and trust/compliance productization. The next 12–18 months are a gating window: breakeven progress can de-risk funding and support sustained compounding into 2031.

Analysis

Thesis

As AI makes biological design and iteration cheap, demand shifts to scarce bottlenecks: reliable DNA “writing” capacity + quality + compliance. If Twist sustains >50% gross margin while scaling volume and productizes biosecurity/provenance (paid trust), it can compound revenue and de-risk financing, supporting a durable tools multiple into 2031.

Last Economy Alignment

AI increases experiment velocity, making high-throughput DNA manufacturing more valuable; Twist captures at the physical product layer (low agent/UI disintermediation) with moderate switching costs via qualification. Alignment is capped by substitution risk (incumbents, modality shifts like enzymatic synthesis) and by the need to turn compliance from overhead into a priced feature.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.6x (from 5 most recent analyses)

Reasoning

The setup is “more designs, more orders”: AI boosts the number of constructs run per program, and Twist’s job is to be the default, high-confidence factory. The stock’s upside is mainly a de-risking path (gross margin durability + EBITDA breakeven) plus steady share gains in DNA and NGS consumables—not a blue-sky platform take-rate story. A mid-single-digit forward EV/Revenue is plausible if profitability is proven and volatility (customer timing, funding cycles) is reduced.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The path is gate-driven: (1) sustain >50% gross margin while scaling qualified output, (2) hit the FY26 breakeven transition to remove dilution/financing overhang, and (3) defend price/volume against incumbents and modality shifts. Regulatory screening can help as a permissioning moat, but only if Twist can monetize “trust” rather than absorb it as overhead.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Trading remained near the 52-week high following the early-February FY26 Q1 results and raised FY26 revenue outlook.
No new fundamental SEC update identified since the FY26 Q1 results package; next major repricing surface is FY26 Q2 results/guidance.
Peer valuations remain bifurcated: profitable bioprocess tools hold higher EV/Sales than earlier-stage genomics tools, keeping TWST’s multiple sensitive to the breakeven narrative.

Forecast update

Slightly more conservative exit multiple to reflect ongoing substitution pressure and the need to prove profitability before a durable re-rate.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.41

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$49.89

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research